Sleep dysfunction and EEG alterations in mice overexpressing alpha-synuclein. by McDowell, Kimberly A et al.
UCLA
UCLA Previously Published Works
Title


















eScholarship.org Powered by the California Digital Library
University of California





Sleep Dysfunction and EEG Alterations in
Mice Overexpressing Alpha-Synuclein
Kimberly A. McDowella, David Shina, Kenneth P. Roosb and Marie-Franc¸oise Chesseleta,∗
aDepartment of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
bDepartment of Physiology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Abstract.
Background: Sleep disruptions occur early and frequently in Parkinson’s disease (PD). PD patients also show a slowing of
resting state activity. Alpha-synuclein is causally linked to PD and accumulates in sleep-related brain regions. While sleep
problems occur in over 75% of PD patients and severely impact the quality of life of patients and caregivers, their study is
limited by a paucity of adequate animal models.
Objective: The objective of this study was to determine whether overexpression of wildtype alpha-synuclein could lead to
alterations in sleep patterns reminiscent of those observed in PD by measuring sleep/wake activity with rigorous quantitative
methods in a well-characterized genetic mouse model.
Methods: At 10 months of age, mice expressing human wildtype alpha-synuclein under the Thy-1 promoter (Thy1-aSyn)
and wildtype littermates underwent the subcutaneous implantation of a telemetry device (Data Sciences International) for the
recording of electromyograms (EMG) and electroencephalograms (EEG) in freelymoving animals. Surgeries and data collection
were performed without knowledge of mouse genotype.
Results: Thy1-aSyn mice showed increased non-rapid eye movement sleep during their quiescent phase, increased active wake
during their active phase, and decreased rapid eye movement sleep over a 24-h period, as well as a shift in the density of their
EEG power spectra toward lower frequencies with a significant decrease in gamma power during wakefulness.
Conclusions: Alpha-synuclein overexpression in mice produces sleep disruptions and altered oscillatory EEG activity reminis-
cent of PD, and this model provides a novel platform to assess mechanisms and therapeutic strategies for sleep dysfunction in
PD.
Keywords: Parkinson disease, Thy1-aSynmice, rapid eyemovement sleep, EEG, power spectra, gamma oscillations, implantable
telemetry
INTRODUCTION
Parkinson’s disease (PD), an incurable and debili-
tating neurodegenerative disease that currently affects
over 4 million people worldwide [1], causes both
motor and non-motor symptoms, including sleep dis-
turbances [2, 3]. While the etiology remains largely
unknown, sleep alterations can precede the onset of
the characteristic motor signs by many years [4].
In particular, excessive daytime sleepiness and REM
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behavioral disorder have been linked to an increased
risk of subsequently developing PD [5–7], suggest-
ing that these changes are a fundamental aspect of
the early pathology of the disease. Pathological alter-
ations in alpha-synuclein, a protein genetically linked
to PD, may provide an anatomical substrate for these
early sleep alterations. Indeed, alpha-synuclein accu-
mulates in the brainstem, a key brain region involved
in sleep/wake activity, at pre-manifest stages of PD
(Braak stages II and III) [8].
Our laboratory has extensively characterized a
mousemodel of alpha-synuclein overexpression under
the Thy-1 promoter (Thy1-aSyn) [9]. These mice
develop early and progressive motor and non-motor
deficits in domains affected in PD and, by 14months of
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age, a loss of striatal dopamine, together with L-dopa
responsive motor deficits [8]. Kudo et al. have doc-
umented progressive alterations in circadian rhythms
in this model [10]. Here, we report that these mice
also show significant disruption of sleep/wake activity
and alterations in EEG oscillations, starting months
before the occurrence of striatal dopamine loss and
L-dopa responsive motor deficits. These data indi-
cate that alpha-synuclein overexpression is sufficient to
induce sleep alterations in mice and identify the Thy1-
aSyn mice as an experimental model for studying the
mechanisms of sleep disruption and EEG alterations
in pre-manifest PD as well as facilitating the testing of
novel therapeutic strategies for this non-motor symp-
tom that severely affects the quality of life of patients.
Furthermore, EEG alterations can provide a highly
translatable endpoint measure for preclinical studies
of novel PD treatments.
MATERIALS AND METHODS
Animals
All animals were treated in accordance with
the guidelines of the University of California Los
Angeles – Institutional Animal Care and Use Com-
mittee. Food and water were provided ad libitum.
Thy1-aSyn mice were developed by the laboratory
of Dr. Eliezer Masliah at UCSD and maintained
on a mixed C57BL/6-DBA/2 background [11]. The
genotypes of all mice were determined by PCR ampli-
fication of tail DNA at 1 month of age and confirmed at
the end of the study. No randomization of groups was
required as mice were assigned based on genotype.
Only male mice were used in this study because fluc-
tuations in ovarian hormones due to the estrous cycle
strongly influence sleep/wake activity [12].
Implantation of radiotelemetry transmitter and
EEG/EMG electrodes
Male Thy1-aSyn mice (n = 9) and their wildtype
(WT) littermates (n = 9) at 9.5–10.5 months of age
underwent a single survival surgery to subcutaneously
implant a telemetry device (Data Sciences Interna-
tional, St. Paul, MN). Mice were anesthetized with
isoflurane and placed in a stereotaxic frame to fix the
body in a prone position. The skin was incised with a
sterile scalpel (2–3 cm incision) along the dorsal mid-
line from the posterior margin of the eyes to a point
midway between the scapulae. Using small, blunt-
tipped, dissecting scissors, a subcutaneous pocket was
formed along the animal’s dorsal flank for placement of
a TL1M2-F20-EET transmitter (Data Sciences Inter-
national, St. Paul, MN). The two leads for measuring
EEGs were implanted epidurally. Using a handheld
drill (0.9 mm micro drill bit) under aseptic conditions,
two burr holes were made in the skull: the first at
+1.0 mm anterior and 1.0 mm lateral to Bregma, the
second 3.0 mm posterior and 3.0 mm lateral to Bregma
on the contralateral side. The burr holes were then
each fitted with a dental screw (00-96 X 1/16 inch),
and an exposed portion of the two EEG leads were
wrapped around the dental screws (one lead per screw)
and secured with dental acrylic. The two EMG leads
were placed in direct contact with the cervical trapezius
muscle, approximately 1–2 mm apart along the same
bundle of muscle fibers. The skin incision was closed
using 5-0 nylon sutures. Animals were individually
housed and allowed 7 days to recover.
EEG/EMG acquisition
After recovery from surgery, electroencephalograms
(EEG) and electromyograms (EMG) were recorded
continuously for 5 days from the freely moving ani-
mals. All recordings took place in a designated area
with minimal noise or other background disturbances;
furthermore, animals were housed within horizon-
tal light-tight wooden cabinets equipped with fans
that allowed for proper ventilation, temperature and
humidity, and light timers to maintain a strict 12:12 h
light/dark cycle. Animals were housed individually
in standard plexiglass home cages on receiver plates
(RPC1, DSI, MN) that sent the EEG and EMG wave-
form data via an exchange matrix (DSI, MN) to a
computer installed with Dataquest ART 4.1 software
(DSI, MN) set to a continuous sampling mode. The data
were collected at a sampling rate of 250 Hz. The ana-
log signal was converted to a digital signal and stored
for future analysis. An experimenter that was unaware
of animal genotype completed all surgical procedures
and telemetry recordings.
Analysis of EEG and EMG data
Previous studies have established that non-tethered
EEG/EMG telemetry recordings can be reliably gener-
ated to assess vigilance states (wakefulness, non-REM
sleep, REM sleep) in mice [13, 14]. Unlike humans,
who are diurnal and exhibit consolidated sleep, mice
are nocturnal and exhibit circadian intervals of activ-
ity/rest cycles. However, mice accumulate the majority
of their wakefulness in the dark period (lights off)
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and the majority of their sleep in the light period
(lights on); therefore, for clarity these phases will
be referred to as the active and quiescent phases,
respectively. One 24-h period (12-h light/dark cycle;
day 3 out of 5 total days recorded) was manually
scored using Neuroscore software (DSI, MN) into 10-
sec epochs of wake, non-REM sleep, or REM sleep.
Wakefulness was characterized by low-amplitude EEG
with mixed high-frequency components combined
with high-amplitude EMG. Whole-body movements
detected by short transistor–transistor logic (TTL)
pulses were automatically recorded from each trans-
mitter and reported as counts per minute, providing a
relative measure of activity (not an absolute measure of
distance traveled). Thus, wake was further categorized
into active wake (presence of a TTL pulse) and quiet
wake (absence of a TTL pulse). Non-REM sleep was
characterized by a relative increase in EEG amplitude
consisting of mainly delta and theta frequency com-
ponents combined with low-EMG tone. REM sleep
was characterized by a low-amplitude theta-based EEG
combined with muscle atonia and occasional mus-
cle twitches (Fig. 1). Electrooculography was not
used to classify REM sleep in this study. Lastly, the
EEG/EMG signal quality obtained with the telemetry
system/electrode placement enabled a trained analyst
to confidently classify vigilance states with minimal
artefacts (<0.1% of all recordings). All 10 sec-epochs
for each stage of sleep were distributed into 2-h bins
for each 12-h quiescent and active phase. To further
explore changes in sleep/wake architecture, we calcu-
lated the number and mean duration of bouts for each
vigilance state. These data were then averaged over 2-h
intervals. Total sleep time (TST) was defined as the sum
of the time spent in non-REM sleep and REM sleep
over each 12-h period. Sleep efficiency was defined
as the percentage of time spent in non-REM sleep and
REM sleep out of each 12-h period. Sleep onset latency
was defined as the average latency from wakefulness
to non-REM sleep. Sleep fragmentation was defined
as the number of arousals from non-REM sleep or
REM sleep over each 12-h period. To access any dif-
ferences in the EEG power spectrum between animals,
we completed a FFT using the Neuroscore software
to obtain the power density values for each frequency
bin (delta = 1–4 Hz, theta = 4–8 Hz, alpha = 8–12 Hz,
beta = 16–24 Hz, gamma = 25–50 Hz) within each vig-
ilant state (wake, non-REM sleep, REM sleep). These
data were then expressed as a percentage of the
mean total power across all frequency bins and
then averaged over the 12-h quiescent and active
phase.
Statistics
The 12-h binned data used to compile Table 1 were
analyzed with a two-tailed Student’s t-test. All other
data were analyzed using a two-way, repeated mea-
sures ANOVA. For the vigilant state and sleep-wake
bouts, the independent variables were defined as geno-
type and zeitgeber time (ZT). For the EEG power
spectra data, the independent variables were defined
as genotype and power band frequency. Multiple com-
parisons were analyzed with the Tukey test. A power
analysis was performed to determine the required
group size to detect either a 30% or a 50% drug effect
(80% power, 5% alpha level) in future pre-clinical drug
studies in Thy1-aSyn mice. Statistical tests were con-
ducted using SigmaPlot Version 12.0, and values of
p < 0.05 were considered significant.
RESULTS
Mice exhibit regular intervals of activity-rest cycles
throughout a 24-h period; however, they accumulate
the majority of their wakefulness in the dark period and
the majority of their sleep in the light period. Analy-
sis of a 24-h period consisting of 12 h of dark (active
phase) and 12 h of light (quiescent phase) revealed
abnormalities in the sleep/wake activity of Thy1-aSyn
mice when compared with WT littermates (Fig. 2).
During the active phase, Thy1-aSyn mice spent signifi-
cantly more time in Active Wake (Fig. 2A, F(1,16) = 6.3,
p = 0.023) and less time in REM sleep (Fig. 2D,
F(1,16) = 10.3,p = 0.005) when compared with controls.
During the quiescent phase, Thy1-aSyn mice show a
significant increase in the amount of time they spent in
non-REM sleep (Fig. 2C, F(1,16) = 10.2, p = 0.006) and
a significant decrease in the time spent in REM sleep
(Fig. 2D, F(1,16) = 7.6, p = 0.014) when compared with
WT littermates.
To further characterize the observed alterations in
vigilant states, we analyzed the sleep/wake archi-
tecture of the mice (Fig. 3 and Table 1). In the
active phase, there were no significant differences
in the number of bouts or mean length for Active
Wake (Fig. 3A, F(1,16) = 1.4, p = 0.25 and F(1,16) = 3.1,
p = 0.099, respectively) or Quiet Wake (Fig. 3B,
F(1,16) = 1.5, p = 0.24 and F(1,16) = 0.01, p = 0.91,
respectively). However, Thy1-aSyn mice showed a sig-
nificant increase in sleep onset latency (time spent in
Active Wake and Quiet Wake before entering non-
REM sleep) during the active phase when compared
with WT mice (Table 1, p = 0.01). We found a signifi-
cant increase in non-REM sleep bout length (Fig. 3C,
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Fig. 1. Representative examples of the EEG and EMG waveforms used for manually scoring the vigilant states of mice.
Table 1
Summary of additional sleep parameters in Thy1-aSyn and WT mice for the active phase (grey) and the quiescent phase (white). Total sleep time
(TST) was defined as the sum of the time spent in non-REM sleep and REM sleep over each 12-h period. Sleep efficiency was defined as the
percentage of time spent in non-REM sleep and REM sleep out of each 12-h period. Sleep onset latency was defined as the average latency from
wakefulness to non-REM sleep. Sleep fragmentation was defined as the number of arousals from non-REM sleep or REM sleep over each 12-h
period. Data are expressed as the mean ± S.E.M. Data were analyzed using a two-tailed Student’s t-test (*p < 0.05, n = 9 WT, n = 9 Thy1-aSyn)
Parameter WT Thy1-aSyn p-value
Total sleep time (min) 321.3 ± 19.6 270.1 ± 27.2 0.15
Sleep efficiency (%) 44.6 ± 2.7 37.5 ± 3.8 0.15
Sleep onset latency (min) 7.9 ± 0.6 14.8 ± 2.4* 0.01
Sleep fragmentation (bout #) 145 ± 10 86 ± 11* 0.001
Total sleep time (min) 400.1 ± 20.3 455.0 ± 17.4 0.06
Sleep efficiency (%) 55.6 ± 2.8 63.2 ± 2.4 0.06
Sleep onset latency (min) 5.8 ± 0.6 4.9 ± 0.6 0.31
Sleep fragmentation (bout #) 152 ± 8 135 ± 8 0.15
F(1,16) = 11.4, p = 0.004); in addition, the Thy1-aSyn
mice spent less time in REM sleep because of a sig-
nificant decrease in the number of bouts (Fig. 3D,
F(1,16) = 4.6, p = 0.047) without a significant decrease
in bout length (Fig. 3D, F(1,16) = 3.2, p = 0.093). Anal-
ysis of sleep fragmentation also revealed a significant
decrease in the number of awakenings from sleep in
Thy1-aSyn mice when compared with their WT litter-
mates (Table 1, p = 0.001). Taken together, these data
show that during their active phase, Thy1-aSyn mice
enter into bouts of REM sleep less often because of
longer bout lengths of non-REM sleep when compared
with WT mice. In the quiescent phase, the significant
increase in non-REM sleep was also due to an increase
in bout length (Fig. 3C, F(1,16) = 24.8, p < 0.001). There
were no significant differences in the number of bouts
or mean length for REM sleep (Fig. 3D, F(1,16) = 2.6,
p = 0.13 and F(1,16) = 0.002, p = 0.96, respectively) in
the quiescent phase between groups. Based on the gen-
eral patterns of sleep architecture in Thy1-aSyn mice,
their sleep dysregulation is not due to sleep fragmen-
tation (i.e., increased number of awakenings or bouts
of specific vigilant states), but rather due to a change
in the overall time spent in each vigilant state (i.e.,
increase in mean bout length).
To access any differences in the EEG spectrum
between animals, we examined the relative power
density within each vigilant state. Generally, Thy1-
aSyn mice show a shift in the density of their power
spectra toward lower frequencies (Fig. 4). Thy1-aSyn
mice show an increase in delta and theta power and a
decrease in gamma power during bouts of either Active
Wake (Fig. 4A, F(1,16) = 20.6, p = 0.0003) or Quiet
Wake (Fig. 4B, F(1,16) = 23.2, p = 0.0002) when com-
pared with WT littermates. During bouts of non-REM
sleep, Thy1-aSyn mice show an increase in delta power
and a decrease in alpha power (Fig. 4C, F(1,16) = 45.3,
p < 0.0001) when compared with WT. During bouts
of REM sleep, Thy1-aSyn mice show an increase in
delta and theta power and a decrease in alpha power
(Fig. 4D, F(1,16) = 56.1, p < 0.0001) when compared
with WT littermates. The light cycle (i.e., whether the
mouse was in its active phase or quiescent phase) did
not influence the differences observed between groups.
Taken together, these data show that Thy1-aSyn mice
exhibit significant alterations in their general cortical
EEG activity.
Upon completion of this study, we conducted a
power analysis to determine if the alterations in
sleep/wake activity and power spectra data were robust
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Fig. 2. Sleep/wake activity of WT and Thy1-aSyn mice. The data are
shown as the mean duration of time (min) ± S.E.M. spent in Active
Wake (A), Quiet Wake (B), non-REM sleep (C), and REM sleep
(D) in 2-h bins for the active phase (black bar) and quiescent phase
(white bar). Data were analyzed using a two-way, repeated measures
ANOVA with Tukey’s multiple comparisons (*p < 0.05, n = 9 WT,
n = 9 Thy1-aSyn).
enough for use as an endpoint measure in future
pre-clinical studies of novel therapeutics (factorial
ANOVA design, 80% power, 5% alpha level) (Table 2).
We determined that the sample size needed to detect a
genotype effect on the time spent in each vigilant state
the study would vary between 2 and 16 mice, with the
larger group needed to detect a change in time spent in
quiet wake. Based on these data in Thy1-aSyn mice,
the study would require between 2 and 10 mice per
group to detect a 50% drug effect, and a group of 6
would be sufficient to detect a 30% drug effect on time
spent in non-REM sleep. For the EEG power spectra
data, detection of a genotype effect would require 3 to
11 mice per group except for the relative percentage of
alpha, which would require an unpractical number of
subjects. To detect a 50% drug effect on these data in
Thy1-aSyn mice, the study would require groups of 3
to 12 mice, and a 30% drug effect could be observed
for most measures with 14 or less mice.
DISCUSSION
Despite the frequency of sleep disorders in PD, few
rodent models of the disease exhibit significant alter-
ations in sleep/wake activity [15]. Here, we report
that 9-10 month-old Thy1-aSyn accumulate less REM
sleep over a 24-h period, and decreased REM sleep
has been reported as a symptom of PD [16]. In addi-
tion, the alpha-synuclein overexpressing mice show a
significant increase in non-REM sleep during the qui-
escent phase and an increase in active wake during
the active phase. Our quantitative assessment of the
sleep/wake activity supports recent work in the Thy1-
aSyn mice that described deficits in circadian rhythms
characterized by lower night-time activity with a
greater fragmentation in wheel-running [10]. To our
knowledge, this is the first report of altered sleep archi-
tecture in a mouse model of synucleinopathy. Mice
overexpressing the A53T mutation of alpha-synuclein
displayed an increase in activity and a decrease in esti-
mated total sleep time; however, this study did not
quantitatively access EEG/EMG activity to distinguish
alterations in specific vigilant states [17]. Interestingly,
two laboratories have recently published a quantitative
assessment of sleep patterns and EEG disturbances in
the R6/2 mouse model of Huntington’s disease. Kantor
et al. found that the R6/2 mice exhibited a progres-
sive fragmentation of wakefulness and increased REM
sleep. In addition, abnormal gamma activity was found
at an older age [18]. Fisher et al. findings also found an
increase in sleep fragmentation. Of note, the increases
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Fig. 3. Sleep architecture of WT and Thy1-aSyn mice. The data are shown as the mean and S.E.M. of each sleep-wake bout (mean number
of bouts and mean bout duration in seconds) for Active Wake (A), Quiet Wake (B), non-REM sleep (C), and REM sleep (D) in 2-h bins for
the active phase (black bar) and quiescent phase (white bar). Data were analyzed using a two-way, repeated measures ANOVA with Tukey’s
multiple comparisons (*p < 0.05, n = 9 WT, n = 9 Thy1-aSyn).
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Fig. 4. EEG power spectra densities of WT and Thy1-aSyn mice. The data were calculated as the percentage of each frequency bin out of the
mean total power across all frequency bins. The results are shown as the mean and S.E.M. for the relative EEG power spectra densities for
Active Wake (A), Quiet Wake (B), non-REM sleep (C), and REM sleep (D). Data were analyzed using a two-way, repeated measures ANOVA
with Tukey’s multiple comparisons (*p < 0.05, n = 9 WT, n = 9 Thy1-aSyn).
Table 2
Power analyses of sleep/wake activity and EEG spectral parameters (factorial ANOVA design, alpha level of 0.05, 80% power)
Parameter Sample size for genotype effect Sample size for 30% drug effect Sample size for 50% drug effect
Sleep/Wake Activity
Time spent in Active Wake (min) 14 28 10
Time spent in Quiet Wake 16 30 11
Time spent in non-REM sleep 10 6 2
Time spent in REM sleep 2 19 7
EEG Spectra
Delta relative percentage 11 8 4
Theta relative percentage 4 4 3
Alpha relative percentage 91 14 6
Beta relative percentage 3 11 5
Gamma relative percentage 3 29 12
in beta and gamma activity in the EEG of R6/2 mice
developed prior to the symptomatic phase of the dis-
ease [19]. Based on this work and the findings from
our current study, future longitudinal and quantitative
analyses of EEG and sleep patterns in animal models of
neurodegeneration will be a valuable tool for differenti-
ating the specific mechanisms behind the pathogenesis
of multiple diseases.
Similar to the R6/2 mice, the sleep alterations we
have observed in the Thy1-aSyn mice occur months
before these mice show deficits in striatal dopamine
and hypoactivity [20]. Even though studies have shown
that DA depletion significantly diminishes REM sleep
[20, 21], the role of DA and DAergic nuclei (i.e., sub-
stantia nigra) in sleep/wake regulation remains unclear
[22]. For example, an acute partial reduction ( 60%)
of striatal DA levels can induce a decrease in REM
sleep without significant changes in motor behavior
[21], which is consistent with the development of sleep
disruptions in PD patients prior to the presentation
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of motor symptoms. However, pathological studies
strongly suggest that dopamine depletion may not be
the only or even the primary culprit for sleep distur-
bances in PD. The occurrence of motor symptoms in
PD is preceded by an extended pre-manifest phase,
which likely corresponds to the progressive accumu-
lation of alpha-synuclein pathology in peripheral and
central neurons [7]. Sleep disturbances are one of
the many non-motor deficits that may precede the
onset of motor symptoms, and they may be related
to pathology in brain regions involved in sleep regula-
tion, such as the raphe nuclei, the locus coeruleus, and
the pedunculopontine nucleus [23]. The Thy1-aSyn
mice show proteinase K-resistant aggregates of alpha-
synuclein from a young age in the locus coeruleus [23],
which may be related to the neuronal dysfunction and
sleep disorders we observed in these mice. Indeed, the
brainstem, including the cholinergic pedunculopontine
nucleus, is a key player in the initiation and mainte-
nance of REM sleep [24, 25]. Furthermore, patients
that underwent deep brain stimulation of this area dis-
play increased REM sleep [26, 27]. Further elucidation
of the brain nuclei involved in the sleep deficits found
in the Thy1-aSyn mouse model will help to advance
our understanding and treatment of the earlier stages
of PD.
Our EEG analysis also revealed significant alter-
ations in the EEG power spectra of Thy1-aSyn mice,
with a significant shift towards lower frequencies and
a decrease in gamma activity. Previous EEG studies
in PD patients have shown an increased incidence
of abnormalities (i.e., slowing of the EEG) that may
relate to memory deficits and cognitive dysfunction
[28, 29], with a greater frequency of EEG slowing in
patients with severe cognitive impairment [30]. Indeed,
decreasing cognitive performance was associated with
increases in delta and theta power, and decreases in
alpha and gamma power in PD patients, whereas motor
impairment correlated only with an increase in theta
power [31]. However, a widespread slowing of oscil-
latory brain activity can already be observed in the
pre-manifest phase of PD, long before any evidence
of dementia, and may result from the degeneration of
noradrenergic or serotonergic corticopetal projections
arising in the brainstem [32]. Interestingly, the Thy1-
aSyn mice show progressive, early cognitive deficits
[33], and these deficits could be related to our EEG
observations.
In conclusion, our data indicate that alpha-synuclein
overexpression is sufficient to produce sleep disorders,
a frequent and early symptom of PD. Furthermore,
pervasive EEG power spectra anomalies point to
widespread cortical and/or hippocampal network dys-
function in this model that is reminiscent of EEG
slowing observed in patients. These results provide
a new mouse model to elucidate the mechanisms of
PD-related sleep dysfunction and develop more effi-
cacious treatments, as indicated by the low number of
animals needed to detect drug effects on many of the
parameters assessed in the present study. Importantly,
the high power to detect drug-induced modifications
of our EEG findings will also provide an endpoint for
preclinical studies in this mouse model that can be later
translated to clinical studies in humans.
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